China Archives

News and Trends 13 Oct 2022

Merck contributing to Jacobio Pharma colorectal cancer clinical trial

Jacobio announced it has entered into a clinical trial collaboration agreement with Merck on a clinical study of combination therapy between Jacobio’s KRAS G12C inhibitor JAB-21822 and Merck’s epidermal growth factor receptor (EGFR) inhibitor Erbitux (cetuximab). This clinical study aims to evaluate the efficacy of JAB-21822 in combination with cetuximab in patients with KRAS G12C-mutated […]

October 13, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 12 Oct 2022

Agreement signed to advance therapy for autoimmune disease

HanAll Biopharma’s licensed partner, Harbour BioMed, has signed an exclusive sublicense agreement with CSPC NBP Pharmaceutical Co., Ltd for an advanced inhibitor. The agreement is for HanAll’s neonatal Fc receptor (FcRn) inhibitor batoclimab which is one of the most advanced being developed in Greater China. The companies say it has the potential to become a […]

October 12, 2022 - 3 minutesmins - By Liza Laws

News and Trends 12 Oct 2022

WuXi Biologics and Toregem BioPharma to develop antibody for adentia treatment

WuXi Biologics and Toregem BioPharma, a biotech startup company from Kyoto University, have signed a memorandum of understanding to form a strategic partnership to develop TRG035. TRG035 is a monoclonal antibody targeting USAG-1 as a tooth regeneration treatment for congenital adentia. Within the partnership, Toregem BioPharma will have access to WuXi Biologics’ integrated CMC services […]

October 12, 2022 - 3 minutesmins - By Jim Cornall

Anastasiia Slynko biotech investment 744x368 1

In Depth 11 Oct 2022

The biggest private biotech investments in September 2022

The companies Acelyrin, InnovaFeed and Arsenal Biosciences bagged the biggest biotech investments in September 2022, with insect protein and cell therapies attracting big funding rounds. Autumn is in full swing in the Northern Hemisphere. After a breather in August 2022, September saw the return of big fundraising activity for biotech companies. We’ve gathered the biggest […]

October 11, 2022 - 3 minutesmins - By Jonathan Smith

News and Trends 10 Oct 2022

JW Therapeutics receives approval for relapsed or refractory follicular lymphoma drug

China’s National Medical Products Administration (NMPA) has approved the supplemental new drug application (sNDA) for JW Therapeutics’ anti-CD19 autologous chimeric antigen receptor T (CAR-T) cell immunotherapy product relmacabtagene autoleucel injection. Also known as relma-cel, the product has the trade name Carteyva. It is used for the treatment of adult patients with follicular lymphoma that is […]

October 10, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 10 Oct 2022

Trial starts for treatment of warm autoimmune hemolytic anemia

China-based Hutchmed has started a phase 2/3 trial of sovleplenib in adults with a disorder called warm antibody autoimmune hemolytic anemia (wAIHA). The autoimmune disorder can lead to anemia and currently has limited treatment options. It causes premature destruction of healthy red blood cells and the rate of production of new cells in the bone […]

October 10, 2022 - 2 minutesmins - By Liza Laws

News and Trends 5 Oct 2022

CanSinoBIO to present latest data on inhaled COVID vaccine

CanSino Biologics Inc. will be presenting clinical trial data for the recombinant COVID-19 vaccine (adenovirus type 5 vector) for inhalation (with the trade name Convidecia Air) at World Vaccine Congress (WVC) Europe to be held October 11 to 14, 2022 in Barcelona, Spain. Jean-Denis Shu, vice president for medical affairs of CanSino Biologics will be […]

October 5, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 29 Sep 2022

NeuShen Therapeutics closes $20M pre-A financing

Chinese biotech company NeuShen Therapeutics, Inc. has closed an approximately $20 million series pre-A financing led by LAPAM, a China based venture capital. The new capital will be used to expand the team and catalyze in-house CNS (central nervous system) drug discovery in both the U.S. and China. “The successful completion of this fundraising is […]

September 29, 2022 - 3 minutesmins - By Jim Cornall

Kintor Pharmaceutical drug gets positive results for breast cancer

News and Trends 29 Sep 2022

Positive results from study of drug to treat patients with breast cancer published

Results from a phase 1b study of a drug to treat patients with androgen receptor positive (AR+) metastatic breast cancer (mBC) in China were published yesterday (September 28). Kintor Pharmaceutical Limited, a clinical stage biotech company has developed Pruxelutamide, an oral new generation AR antagonist which has shown promising activity in heavily pretreated AR+ mBC […]

September 29, 2022 - 3 minutesmins - By Liza Laws

CAR-T cell therapy, cancer therapy, cell therapy

News and Trends 27 Sep 2022

Bioheng Biotech has positive CAR-T cell therapy results published in academic journal

Positive results from a phase 1 clinical study of RD13-01, an anti-CD7 universal CAR-T therapy product, have been published in reputable academic journal, Cell Research. China-based Bioheng Biotech Co. Ltd, a clinical-stage biotechnology company focused on developing novel cellular immunotherapy made the announcement today (September 27). The results published with the title of ‘CD7-targeted allogeneic CAR-T […]

September 27, 2022 - 3 minutesmins - By Liza Laws

News and Trends 27 Sep 2022

Angel Pharma announces approval of IND application for clinical trial of mupadolimab

Approval of an investigational new drug (IND) application for mupadolimab has been granted by the Center for Drug Evaluation (CDE) to initiate a phase 1/1b clinical trial in China. Angel Pharma, a clinical stage biopharmaceutical company owns the rights to mupadolimab in Greater China. Mupadolimab is a humanized monoclonal antibody directed against CD73. In preclinical […]

September 27, 2022 - 2 minutesmins - By Liza Laws

News and Trends 26 Sep 2022

Everest Medicines gets go-ahead for renal disease drug study

Chinese biopharma company Everest Medicines says the China National Medical Products Administration (NMPA)’s Center for Drug Evaluation has approved the investigational new drug (IND) application for a phase 1b study of EVER001, a next-generation covalent reversible Bruton’s tyrosine kinase (BTK) inhibitor, in development for the treatment of glomerular diseases. The planned phase 1b clinical study […]

September 26, 2022 - 2 minutesmins - By Jim Cornall

Knowledge hub

Categories

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Approaches

Therapeutic areas

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

China

Merck contributing to Jacobio Pharma colorectal cancer clinical trial

Agreement signed to advance therapy for autoimmune disease

WuXi Biologics and Toregem BioPharma to develop antibody for adentia treatment

The biggest private biotech investments in September 2022

JW Therapeutics receives approval for relapsed or refractory follicular lymphoma drug

Trial starts for treatment of warm autoimmune hemolytic anemia

CanSinoBIO to present latest data on inhaled COVID vaccine

NeuShen Therapeutics closes $20M pre-A financing

Positive results from study of drug to treat patients with breast cancer published

Bioheng Biotech has positive CAR-T cell therapy results published in academic journal

Angel Pharma announces approval of IND application for clinical trial of mupadolimab

Everest Medicines gets go-ahead for renal disease drug study

Subscribe to our newsletter to get the latest biotech news!

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!